Shots:

• The companies collaborated to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. StrideBio will be responsible for research- development and manufacturing of the first four CNS targets which include MECP2 (Rett syndrome)- SCN1A (Dravet syndrome)- UBE3A (Angelman syndrome)- and NPC1 (Niemann-Pick)
• Stride Bio to receive $48M upfront in cash & Sarepta’s shares- development- regulatory & commercial milestones for 4 programs and royalties on sales of products developed via collaboration. Sarepta to get an exclusive license on selected targets leveraging StrideBio’s capsid technology
• Additionally- Sarepta to get an exclusive option to expand the collaboration for up to additional four targets in exchange of ~ $42.5M with milestones and an option to obtain co-development and co-commercial rights for one target

Click here to­ read full press release/ article | Ref: Sarepta | Image:  Bloomberg